Virtual trials

February 15, 2023: This Week’s PCT Grand Rounds Will Feature the Heartline Trial of the Apple Watch to Detect Atrial Fibrillation

Posted on by Damon Seils

Headshot of C. Michael GibsonIn this Friday’s PCT Grand Rounds, Dr. C. Michael Gibson of Harvard Medical School will present “The Heartline Trial: A New Paradigm in Conducting Virtual Clinical Trials.”

The Grand Rounds session will be held on Friday, February 17, 2023, at 1:00 pm eastern.

Gibson is a professor of medicine at Harvard Medical School, an interventional cardiologist at Beth Israel Lahey Health, and CEO and president of the nonprofit Baim Institute for Clinical Research and the PERFUSE Study Group. He will discuss the Heartline trial, a virtual randomized controlled trial assessing the effectiveness of the Apple Watch in detecting new-onset atrial fibrillation to reduce stroke, myocardial infarction, and all-cause mortality.

Join the online meeting.

March 9, 2021: COVID-19 Grand Rounds Continues With the Gates MRI Virtual COVID-19 Trial

Posted on by Damon Seils

Drs. Mohamed Bassyouni and Jintanat AnanworanichIn this week’s COVID-19 Grand Rounds session, Drs. Mohamed Bassyouni and Jintanat Ananworanich of the Bill and Melinda Gates Medical Research Institute will present “Lessons Learned From the Gates MRI Virtual COVID-19 Trial.” The Grand Rounds session will be held on Friday, March 12, at 1:00 pm eastern. Join the online meeting.

The NIH Collaboratory Coordinating Center is using its popular Grand Rounds platform to share late-breaking research and promote resources in support of clinical researchers affected by the COVID-19 public health emergency.

 

For previous COVID-19 Grand Rounds, and more news and resources related to the COVID-19 public health emergency, see the COVID-19 Resources page.

October 30, 2020: Lessons from Virtual Trials in Time of a Pandemic: Minnesota Hydroxychloroquine Experience (David Boulware, MD, MPH)

Posted on by Gina Uhlenbrauck

Speaker

David R. Boulware MD, MPH
Professor of Medicine
Infectious Disease & International Medicine
Department of Medicine
University of Minnesota

Topic

Lessons from Virtual Trials in Time of a Pandemic: Minnesota Hydroxychloroquine Experience

Keywords

COVID-19; Patient-reported outcomes (PROs); Hydroxychloroquine; Epidemiology; Virtual trials

Key Points

  • These virtual randomized controlled trials evaluated hydroxychloroquine as a post-exposure prophylaxis, pre-emptive early treatment, and pre-exposure prophylaxis for COVID-19.
  • The trial of post-exposure prophylaxis employed patient-reported outcomes around COVID-19 symptoms and severity as well as side effects of hydroxychloroquine.
  • Enrollment and screening of eligible participants was automated through a REDCap survey.

Discussion Themes

Being a virtual trial, were there concerns about practicing medicine “across state lines?”

There has been a mix of science and politics over the course of the COVID-19 pandemic. Because your trial had substantial media coverage, how did the publicity affect enrollment?

Many big strategy questions can be studied virtually. What changes do you see for trials during future pandemics?

Read reports of these virtual trials in New England Journal of Medicine, Annals of Internal Medicine, and the medRxiv preprint server.

Tags

#pctGR, @Collaboratory1